Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398120 | 1.00 | KMT2A (0.66) | KMT2ATSHRMEN1SIGMAR1OPRK1 | |
| SCHEMBL31010347 | 0.89 | KMT2A (0.61) | KMT2ATSHRMEN1SIGMAR1CYP2D6 | |
| SCHEMBL17342294 | 0.89 | KMT2A (0.61) | KMT2ATSHRMEN1SIGMAR1CYP2D6 | |
| SCHEMBL9267311 | 0.87 | SIGMAR1 (0.56) | KMT2ATSHRMEN1SIGMAR1OPRK1 | |
| SCHEMBL28702566 | 0.86 | SIGMAR1 (0.62) | KMT2ATSHRMEN1SIGMAR1CYP2D6 | |
| SCHEMBL11031008 | 0.86 | SIGMAR1 (0.62) | KMT2ATSHRMEN1SIGMAR1CYP2D6 | |
| SCHEMBL6190817 | 0.86 | SIGMAR1 (0.54) | KMT2ATSHRMEN1SIGMAR1OPRK1 | |
| SCHEMBL3824786 | 0.86 | SIGMAR1 (0.54) | KMT2ATSHRMEN1SIGMAR1OPRK1 | |
| SCHEMBL27416851 | 0.86 | OPRK1 (0.58) | KMT2ATSHRMEN1SIGMAR1OPRK1 | |
| SCHEMBL7733774 | 0.84 | MAPT (0.55) | KMT2ATSHRMEN1SIGMAR1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146629-A1 | MODULATOR FOR PROMOTING BINDING OF BUTYROPHILIN 3A1/2A1 | 北京清辉联诺生物科技有限责任公司 | 2024-07-11 | — | — | WO | disclosed |
| US-8012975-B2 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A. (ES) | 2011-09-06 | — | — | US | disclosed |
| US-20080194798-A1 | Novel Iminecalixarene Derivatives, Method for Preparing the Same, Self-Assembled Monolayer Prepared by Using the Iminecalixarene Derivatives or Aminocalixarene, and Protein Chip Using the Self-Assembled Monolayer | BIOMETRIX TECHNOLOGY INC. (KR) | 2008-08-14 | — | — | US | disclosed |
| US-7410969-B2 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2008-08-12 | — | — | US | disclosed |
| US-20080051407-A1 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A., A MADRID SPAIN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| EP-1496060-B1 | Antitumoral analogs of ET-743 | PHARMA MAR SA (ES) | 2007-08-01 | — | — | EP | disclosed |
| US-7247629-B2 | Antitumoral analogs of et-743 | PHARMA MAR, S.A. | 2007-07-24 | — | — | US | disclosed |
| WO-2007052879-A1 | NOVEL IMINECALIXARENE DERIVATES, METHOD FOR PREPARING THE SAME, SELF-ASSEMBLED MONOLAYER PREPARED BY USING THE IMINECALIXARENE DERIVATES OR AMINOCALIXARENE, AND PROTEIN CHIP USING THE SELF-ASSEMBLED MONOLAYER | BIOMETRIX TECHNOLOGY INC (KR) | 2007-05-10 | — | — | WO | disclosed |
| US-20060019960-A1 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2006-01-26 | — | — | US | disclosed |
| US-20050221456-A1 | Use of indanoyl amide to stimulate secondary metabolism in Taxus sp. | PHYTON BIOTECH, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| EP-1496060-A1 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| EP-1289999-B1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR SA (ES) | 2004-11-17 | — | — | EP | disclosed |
| US-20040019056-A1 | Anititumoral analogs of et-743 | PHARMA MAR, S.A. (ES) | 2004-01-29 | — | — | US | disclosed |
| EP-1289999-A1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR, S.A. (ES) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001087894-A1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR, S.A. (ES) | 2001-11-22 | — | — | WO | disclosed |
| US-5480871-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | CHIRON CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995027729-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| WO-1995004072-A1 | PEPTOID ALPHA-1 ADRENERGIC RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194798-A1 | Novel Iminecalixarene Derivatives, Method for Preparing the Same, Self-Assembled Monolayer Prepared by Using the Iminecalixarene Derivatives or Aminocalixarene, and Protein Chip Using the Self-Assembled Monolayer | STUB1, SPEN, AURKC | KMT2A 1260/4885TSHR 4193/4885MEN1 4200/4885 |
| US-20040019056-A1 | Anititumoral analogs of et-743 | ETV1, ETV6, MATR3 | KMT2A 2948/4885TSHR 2079/4885MEN1 322/4885 |
| US-20080051407-A1 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | FN1, RCN1, ERCC4 | KMT2A 3807/4885TSHR 3384/4885MEN1 220/4885 |
| US-20060019960-A1 | Antitumoral analogs of ET-743 | ETV1, ETV6, ETF1 | KMT2A 4040/4885TSHR 2288/4885MEN1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.